pyrazines has been researched along with losartan potassium in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (30.00) | 29.6817 |
| 2010's | 7 (70.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alsina, M; Djulbegovic, B; Durie, BG; Kumar, A; Loughran, T | 1 |
| Gisslinger, H; Kees, M | 1 |
| Anderson, KC; Bladé, J; Cavenagh, J; Esseltine, DL; Harousseau, JL; Jakubowiak, AJ; Lonial, S; Rajkumar, SV; Richardson, PG; San Miguel, J; Schuster, MW; Sonneveld, P | 1 |
| O'Connell, C; Schroyens, W; Sykes, DB | 2 |
| Alexander, MP; Méndez, GP; Nasr, SH; Rennke, HG; Watson, DC | 1 |
| Korde, N; Kwok, M; Landgren, O | 1 |
| Chopp, M; Zhang, L; Zhang, ZG | 1 |
| Nie, J; Wang, F; Wang, H; Zhang, C | 1 |
| Estepp, JH | 1 |
5 review(s) available for pyrazines and losartan potassium
| Article | Year |
|---|---|
Management of multiple myeloma: a systematic review and critical appraisal of published studies.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Diphosphonates; Drug Administration Schedule; Epoetin Alfa; Erythropoietin; Hematinics; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Multiple Myeloma; Neoplasm Staging; Pyrazines; Randomized Controlled Trials as Topic; Recombinant Proteins; Salvage Therapy; Survival Analysis; Time Factors; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome | 2003 |
Therapy strategies for multiple myeloma: current status.
Topics: Adjuvants, Immunologic; Aged; Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Dexamethasone; Diphosphonates; Drug Therapy, Combination; Erythropoietin; Glucocorticoids; Growth Inhibitors; Humans; Immunosuppressive Agents; Middle Aged; Multiple Myeloma; Oxides; Peripheral Blood Stem Cell Transplantation; Protease Inhibitors; Pyrazines; Randomized Controlled Trials as Topic; Stem Cell Transplantation; Thalidomide; Time Factors; Transplantation, Autologous; Transplantation, Homologous | 2003 |
Renal crescentic alpha heavy chain deposition disease: a report of 3 cases and review of the literature.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cutis Laxa; Dexamethasone; Diabetic Nephropathies; Erythropoietin; Fatal Outcome; Female; Heavy Chain Disease; Hematuria; Humans; Hypertension, Renal; Immunoglobulin alpha-Chains; Immunoglobulin gamma-Chains; Immunoglobulin mu-Chains; Kidney Glomerulus; Male; Multiple Myeloma; Paraproteinemias; Proteinuria; Pyrazines; Thalidomide; Urticaria; Vasculitis, Leukocytoclastic, Cutaneous | 2011 |
The neurovascular unit and combination treatment strategies for stroke.
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Boronic Acids; Bortezomib; Cerebral Hemorrhage; Drug Therapy, Combination; Erythropoietin; Fibrinolytic Agents; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Minocycline; Pyrazines; Stroke; Tissue Plasminogen Activator | 2012 |
Protective factors in diabetic retinopathy: focus on blood-retinal barrier.
Topics: Animals; Blood-Retinal Barrier; Diabetic Retinopathy; Erythropoietin; Fenofibrate; Humans; Insulin-Like Growth Factor Binding Protein 3; Macular Edema; Protective Factors; Pyrazines; Sitagliptin Phosphate; Triazoles; Vascular Endothelial Growth Factor A | 2014 |
5 other study(ies) available for pyrazines and losartan potassium
| Article | Year |
|---|---|
Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma.
Topics: Boronic Acids; Bortezomib; Clinical Trials as Topic; Dexamethasone; Drug Therapy, Combination; Erythropoietin; Female; Humans; Immunosuppressive Agents; Logistic Models; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pulmonary Embolism; Pyrazines; Recombinant Proteins; Recurrence; Risk; Treatment Outcome; Venous Thrombosis | 2008 |
The TEMPI syndrome--a novel multisystem disease.
Topics: Adult; Boronic Acids; Bortezomib; Erythropoietin; Female; Humans; Hydronephrosis; Lymphangiectasis; Male; Middle Aged; Paraproteinemias; Polycythemia; Protease Inhibitors; Pyrazines; Syndrome; Telangiectasis | 2011 |
Bortezomib to treat the TEMPI syndrome.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Erythropoietin; Female; Humans; Lymphangiectasis; Middle Aged; Paraproteinemias; Polycythemia; Pyrazines; Syndrome; Telangiectasis | 2012 |
Complete and partial responses of the TEMPI syndrome to bortezomib.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Erythropoietin; Female; Humans; Male; Middle Aged; Paraproteinemias; Polycythemia; Pyrazines; Syndrome; Telangiectasis | 2012 |
Voxelotor (GBT440), a first-in-class hemoglobin oxygen-affinity modulator, has promising and reassuring preclinical and clinical data.
Topics: Adult; Anemia, Sickle Cell; Animals; Benzaldehydes; Cerebrovascular Circulation; Child; Clinical Trials as Topic; Double-Blind Method; Drug Evaluation, Preclinical; Erythropoietin; Gene Knock-In Techniques; Hematologic Agents; Hemoglobin, Sickle; Humans; Hypoxia; Mice; Mice, Transgenic; Oxygen; Polymerization; Pyrazines; Pyrazoles; Reticulocytes | 2018 |